The Claim
In obese ZSF1 rats with HFpEF, semaglutide treatment increases hepatic expression of FXR (Nr1h4) and decreases expression of LXR (Nr1h2, Nr1h3), resulting in a shift in liver cholesterol metabolism toward increased fatty acid oxidation and reduced cholesterol synthesis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese rats with heart failure and preserved ejection fraction, semaglutide alters liver gene activity to promote fat burning and reduce cholesterol production.
See the scientific wording
In obese ZSF1 rats with HFpEF, semaglutide treatment increases hepatic expression of FXR (Nr1h4) and decreases expression of LXR (Nr1h2, Nr1h3), suggesting a shift in liver cholesterol metabolism toward increased fatty acid oxidation and reduced cholesterol synthesis.
A signaling molecule activates receptors on liver cells, which turns up a gene that helps burn fat and turns down genes that make cholesterol. This causes the liver to stop storing fat and start using it for energy instead, reducing fat buildup and cholesterol levels.
What the research says
1 studyIn obese rats with heart failure, a drug called semaglutide turned on a gene that helps the liver burn fat and turned off genes that make cholesterol, which is exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.